Literature DB >> 7938455

Radiotoxicity of platinum-195m-labeled trans-platinum (II) in mammalian cells.

R W Howell1, A I Kassis, S J Adelstein, D V Rao, H A Wright, R N Hamm, J E Turner, K S Sastry.   

Abstract

The chemotoxicity and radiotoxicity of trans-dichlorodiammineplatinum (II) labeled with 195mPt (trans-195mPt) are investigated to ascertain the potential of radioplatinum coordination complexes as antineoplastic agents. Platinum-195m, with a half-life of about 4 days, is a prolific emitter of low-energy Auger electrons because of the high probability of internal conversion in its isomeric transitions. The kinetics of cellular uptake and retention after incubation and the radiotoxicity of this Auger electron emitter in the form of trans-195mPt is investigated using cells of the Chinese hamster V79 cell line. The cellular uptake of 195mPt reaches a plateau in about 3 to 5 h of incubation and varies nonlinearly with the extracellular concentration of radioactivity. The radioactivity is eliminated from the cells after incubation with an effective half-life of 24 h. Cell survival data, when corrected for the chemical toxicity of nonradiolabeled trans-platinum, give a cell survival curve typical for radiations with high linear energy transfer. At 37% survival, the mean lethal cellular uptake is about 1.0 mBq/cell. Dosimetric considerations, based on subcellular distribution of the radionuclide, yield a value of 4.8 for the relative biological effectiveness when compared with 250 kVp X rays. Theoretical Monte Carlo track-structure calculations indicate that the density of radical species produced in liquid water in the immediate vicinity of a 195mPt decay site is substantially greater than the density of species along the track of a 5.3 MeV alpha particle. This explains qualitatively the efficacy of 195mPt in causing high-LET radiation type biological effects. The extreme radiotoxicity of intranuclearly localized 195mPt, in conjunction with the proclivity of platinum chemotherapy agents to bind to DNA in the cell nucleus, suggests that the combination of chemical effects and the effects of Auger electrons that can be obtained with radioplatinum coordination complexes may have potential in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7938455      PMCID: PMC9319989     

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   3.372


  35 in total

1.  Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers.

Authors:  E R DeSombre; R C Mease; A Hughes; P V Harper; O T DeJesus; A M Friedman
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

2.  The in vitro radiobiology of astatine-211 decay.

Authors:  A I Kassis; C R Harris; S J Adelstein; T J Ruth; R Lambrecht; A P Wolf
Journal:  Radiat Res       Date:  1986-01       Impact factor: 2.841

3.  Radiotoxicity of 125I-iododeoxyuridine in pre-implantation mouse embryos.

Authors:  V R Narra; R W Howell; K H Thanki; D V Rao
Journal:  Int J Radiat Biol       Date:  1991-09       Impact factor: 2.694

4.  On the equivalent dose for Auger electron emitters.

Authors:  R W Howell; V R Narra; K S Sastry; D V Rao
Journal:  Radiat Res       Date:  1993-04       Impact factor: 2.841

5.  Quantitative analysis of cis-dichlorodiammineplatinum(II) by high-performance thin-layer chromatography.

Authors:  B De Spiegeleer; G Slegers; W Van den Bossche; P De Moerloose
Journal:  J Chromatogr       Date:  1984-12-19

6.  In vivo effects of iron-55 and iron-59 on mouse testes: biophysical dosimetry of Auger electrons.

Authors:  D V Rao; K S Sastry; G F Govelitz; H E Grimmond; H Z Hill
Journal:  J Nucl Med       Date:  1985-12       Impact factor: 10.057

7.  5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model.

Authors:  J Baranowska-Kortylewicz; G M Makrigiorgos; A D Van den Abbeele; R M Berman; S J Adelstein; A I Kassis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-11       Impact factor: 7.038

8.  Radiotoxicity of an 125I-labeled DNA intercalator in mammalian cells.

Authors:  A I Kassis; F Fayad; B M Kinsey; K S Sastry; S J Adelstein
Journal:  Radiat Res       Date:  1989-05       Impact factor: 2.841

9.  Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans.

Authors:  A I Kassis; A D Van den Abbeele; P Y Wen; J Baranowska-Kortylewicz; R A Aaronson; W C DeSisto; L A Lampson; P M Black; S J Adelstein
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

10.  Biological toxicity of Auger emitters: molecular fragmentation versus electron irradiation.

Authors:  K G Hofer; G Keough; J M Smith
Journal:  Curr Top Radiat Res Q       Date:  1978-01
View more
  12 in total

1.  A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.

Authors:  John M Akudugu; Roger W Howell
Journal:  Nucl Med Biol       Date:  2012-04-14       Impact factor: 2.408

2.  Molecular and cellular radiobiological effects of Auger emitting radionuclides.

Authors:  Amin I Kassis
Journal:  Radiat Prot Dosimetry       Date:  2010-11-24       Impact factor: 0.972

3.  A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.

Authors:  Raghu Raghavan; Roger W Howell; Michael R Zalutsky
Journal:  Biomed Phys Eng Express       Date:  2017-05-05

4.  Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs.

Authors:  John M Akudugu; Roger W Howell
Journal:  Int J Radiat Biol       Date:  2011-12-09       Impact factor: 2.694

5.  Modeling multicellular response to nonuniform distributions of radioactivity: differences in cellular response to self-dose and cross-dose.

Authors:  Roger W Howell; Prasad V S V Neti
Journal:  Radiat Res       Date:  2005-02       Impact factor: 2.841

6.  Development of Novel 191Pt-Labeled Hoechst33258: 191Pt Is More Suitable than 111In for Targeting DNA.

Authors:  Honoka Obata; Atsushi B Tsuji; Katsushi Kumata; Hitomi Sudo; Katsuyuki Minegishi; Kotaro Nagatsu; Hideo Takakura; Mikako Ogawa; Akihiro Kurimasa; Ming-Rong Zhang
Journal:  J Med Chem       Date:  2022-03-31       Impact factor: 8.039

7.  Radioprotection against lethal damage caused by chronic irradiation with radionuclides in vitro.

Authors:  R W Howell; S M Goddu; A Bishayee; D V Rao
Journal:  Radiat Res       Date:  1998-10       Impact factor: 2.841

Review 8.  Auger processes in the 21st century.

Authors:  Roger W Howell
Journal:  Int J Radiat Biol       Date:  2008-12       Impact factor: 2.694

9.  In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([189, 191Pt]cisplatin) Emitting Auger Electrons.

Authors:  Honoka Obata; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Katsuyuki Minegishi; Kotaro Nagatsu; Mikako Ogawa; Ming-Rong Zhang
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

10.  Cell-killing efficiency and number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with combinations of trans-diaminedichloroplatinum(II) and hyperthermia.

Authors:  M Akaboshi; K Kawai; Y Kinashi; S Masunaga; K Ono
Journal:  Jpn J Cancer Res       Date:  1997-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.